THÔNG TIN TÀI LIỆU
85 Coppini R, Ferrantini C, Yao L, et al Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy Circulation 2013;127(5):575–584 86 Georgakopoulos D, Christe ME, Giewat M, et al The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation Nat Med 1999;5(3):327–330 87 Alves ML, Gaffin RD, Wolska BM Rescue of familial cardiomyopathies by modifications at the level of sarcomere and ca2+ fluxes J Mol Cell Cardiol 2010;48(5):834–842 88 Fatkin D, McConnell BK, Mudd JO, et al An abnormal ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy J Clin Invest 2000;106(11):1351–1359 89 Coppini R, Mazzoni L, Ferrantini C, et al Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy Circ Heart Fail 2017;10(3) 90 Kohler J, Winkler G, Schulte I, et al Mutation of the myosin converter domain alters cross-bridge elasticity Proc Natl Acad Sci USA 2002;99(6):3557–3562 91 Spudich JA Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases Biophys J 2014;106(6):1236–1249 92 Spudich JA The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy Biochem Soc Trans 2015;43(1):64–72 93 Crilley JG, Boehm EA, Blair E, et al Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy J Am Coll Cardiol 2003;41(10):1776–1782 94 Abozguia K, Elliott P, McKenna W, et al Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy Circulation 2010;122(16):1562–1569 95 Green EM, Wakimoto H, Anderson RL, et al A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice Science 2016;351(6273):617–621 96 Beadle RM, Williams LK, Kuehl M, et al Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy JACC Heart Fail 2015;3(3):202–211 97 Ho CY, Lakdawala NK, Cirino AL, et al Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression JACC Heart Fail 2015;3(2):180– 188 98 Olivotto I, Hellawell JL, Farzaneh-Far R, et al Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial Circ Heart Fail 2016;9(3):e002764 99 Ho CY, McMurray JJV, Cirino AL, et al The design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) trial Am Heart J 2017;187:145–155 100 Aoki Y, Niihori T, Kawame H, et al Germline mutations in HRAS proto-oncogene cause costello syndrome Nat Genet 2005;37(10):1038–1040 101 Burch M, Sharland M, Shinebourne E, et al
Ngày đăng: 22/10/2022, 12:39
Xem thêm: